Early Phase 1 Data Support PHA121 as Oral HAE Prophylactic

Early Phase 1 Data Support PHA121 as Oral HAE Prophylactic

299937

Early Phase 1 Data Support PHA121 as Oral HAE Prophylactic

Multiple doses of PHA121 (PHA-022121), an investigational oral therapy for hereditary angioedema (HAE), were well-tolerated and rapidly reached therapeutic levels in healthy volunteers, according to data from a Phase 1 clinical trial. The therapy’s pharmacological profile “suggests that the therapeutic effect of PHA121 can be achieved as early as the first day of dosing, with steady-state plasma levels achieved within three days,” Peng Lu, MD, PhD, chief medical officer of Pharvaris, which is developing the…

You must be logged in to read/download the full post.